Oncology News

Patients treated for hepatocellular carcinoma who had a lower dietary fat intake experienced slower recovery from invasive therapies in a recent study.

Factors that most influence hepatocellular carcinoma risk varied between sex and race among elderly patients, but diabetes and obesity had the greatest overall effect in a recent study.

Factors that most influence hepatocellular carcinoma risk varied between sex and race among elderly patients, but diabetes and obesity had the greatest overall effect in a recent study.

Despite a poor prognosis, improved survival was observed among patients with infiltrative hepatocellular carcinoma after sorafenib or transarterial chemoembolization therapy in a recent study.

Bayer HealthCare Pharmaceuticals recently launched a phase 3 trial assessing the safety and efficacy of regorafenib for patients with hepatocellular carcinoma who experienced disease progression after therapy with sorafenib, according to a press release.

The long-term risk for hepatocellular carcinoma among patients with hepatitis C remains up to 8 years after sustained virological response to antiviral therapy, researchers reported in Clinical Infectious Diseases.

The long-term risk for hepatocellular carcinoma among patients with hepatitis C remains up to 8 years after sustained virological response to antiviral therapy, researchers reported in Clinical Infectious Diseases.

Elderly patients unable to complete daily living tasks without assistance are at particularly increased risk for complications and mortality after hepatic resection, according to a recent study.

Patients with infiltrative hepatocellular carcinoma experienced prolonged survival when treated with transarterial chemoembolization or sorafenib in a recent retrospective cohort study.

Patients with infiltrative hepatocellular carcinoma experienced prolonged survival when treated with transarterial chemoembolization or sorafenib in a recent retrospective cohort study.